U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211802) titled 'CKM For Safe Use of SGLT2i in Type 1 Diabetes' on June 16.
Brief Summary: This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Type 1 Diabetes (T1D)
Intervention:
DRUG: Sotagliflozin Low Dose
200 mg Sotagliflozin, once daily for 6 weeks
DRUG: Sotagliflozin High Dose
400 mg Sotagliflozin, once daily for 6 weeks
DEVICE: Dual Continuous Glucose and Ketone Monitor
Abbott Libre X du...